These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 24446489)

  • 1. Reduced BMPR2 expression induces GM-CSF translation and macrophage recruitment in humans and mice to exacerbate pulmonary hypertension.
    Sawada H; Saito T; Nickel NP; Alastalo TP; Glotzbach JP; Chan R; Haghighat L; Fuchs G; Januszyk M; Cao A; Lai YJ; Perez Vde J; Kim YM; Wang L; Chen PI; Spiekerkoetter E; Mitani Y; Gurtner GC; Sarnow P; Rabinovitch M
    J Exp Med; 2014 Feb; 211(2):263-80. PubMed ID: 24446489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Codependence of Bone Morphogenetic Protein Receptor 2 and Transforming Growth Factor-β in Elastic Fiber Assembly and Its Perturbation in Pulmonary Arterial Hypertension.
    Tojais NF; Cao A; Lai YJ; Wang L; Chen PI; Alcazar MAA; de Jesus Perez VA; Hopper RK; Rhodes CJ; Bill MA; Sakai LY; Rabinovitch M
    Arterioscler Thromb Vasc Biol; 2017 Aug; 37(8):1559-1569. PubMed ID: 28619995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endothelin-Bone morphogenetic protein type 2 receptor interaction induces pulmonary artery smooth muscle cell hyperplasia in pulmonary arterial hypertension.
    Maruyama H; Dewachter C; Belhaj A; Rondelet B; Sakai S; Remmelink M; Vachiery JL; Naeije R; Dewachter L
    J Heart Lung Transplant; 2015 Mar; 34(3):468-78. PubMed ID: 25447587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In Pulmonary Arterial Hypertension, Reduced BMPR2 Promotes Endothelial-to-Mesenchymal Transition via HMGA1 and Its Target Slug.
    Hopper RK; Moonen JR; Diebold I; Cao A; Rhodes CJ; Tojais NF; Hennigs JK; Gu M; Wang L; Rabinovitch M
    Circulation; 2016 May; 133(18):1783-94. PubMed ID: 27045138
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dysregulated Smooth Muscle Cell BMPR2-ARRB2 Axis Causes Pulmonary Hypertension.
    Wang L; Moonen JR; Cao A; Isobe S; Li CG; Tojais NF; Taylor S; Marciano DP; Chen PI; Gu M; Li D; Harper RL; El-Bizri N; Kim YM; Stankunas K; Rabinovitch M
    Circ Res; 2023 Mar; 132(5):545-564. PubMed ID: 36744494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inflammation, endothelial injury, and persistent pulmonary hypertension in heterozygous BMPR2-mutant mice.
    Song Y; Coleman L; Shi J; Beppu H; Sato K; Walsh K; Loscalzo J; Zhang YY
    Am J Physiol Heart Circ Physiol; 2008 Aug; 295(2):H677-90. PubMed ID: 18552156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Critical role for the advanced glycation end-products receptor in pulmonary arterial hypertension etiology.
    Meloche J; Courchesne A; Barrier M; Carter S; Bisserier M; Paulin R; Lauzon-Joset JF; Breuils-Bonnet S; Tremblay É; Biardel S; Racine C; Courture C; Bonnet P; Majka SM; Deshaies Y; Picard F; Provencher S; Bonnet S
    J Am Heart Assoc; 2013 Jan; 2(1):e005157. PubMed ID: 23525442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CCL5 deficiency rescues pulmonary vascular dysfunction, and reverses pulmonary hypertension via caveolin-1-dependent BMPR2 activation.
    Nie X; Tan J; Dai Y; Liu Y; Zou J; Sun J; Ye S; Shen C; Fan L; Chen J; Bian JS
    J Mol Cell Cardiol; 2018 Mar; 116():41-56. PubMed ID: 29374556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BMPRII influences the response of pulmonary microvascular endothelial cells to inflammatory mediators.
    Vengethasamy L; Hautefort A; Tielemans B; Belge C; Perros F; Verleden S; Fadel E; Van Raemdonck D; Delcroix M; Quarck R
    Pflugers Arch; 2016 Nov; 468(11-12):1969-1983. PubMed ID: 27816994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic ablation of the BMPR2 gene in pulmonary endothelium is sufficient to predispose to pulmonary arterial hypertension.
    Hong KH; Lee YJ; Lee E; Park SO; Han C; Beppu H; Li E; Raizada MK; Bloch KD; Oh SP
    Circulation; 2008 Aug; 118(7):722-30. PubMed ID: 18663089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BMPR2 mutation alters the lung macrophage endothelin-1 cascade in a mouse model and patients with heritable pulmonary artery hypertension.
    Talati M; West J; Blackwell TR; Loyd JE; Meyrick B
    Am J Physiol Lung Cell Mol Physiol; 2010 Sep; 299(3):L363-73. PubMed ID: 20562228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Autophagy contributes to BMP type 2 receptor degradation and development of pulmonary arterial hypertension.
    Gomez-Puerto MC; van Zuijen I; Huang CJ; Szulcek R; Pan X; van Dinther MA; Kurakula K; Wiesmeijer CC; Goumans MJ; Bogaard HJ; Morrell NW; Rana AA; Ten Dijke P
    J Pathol; 2019 Nov; 249(3):356-367. PubMed ID: 31257577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular effects of loss of BMPR2 signaling in smooth muscle in a transgenic mouse model of PAH.
    Tada Y; Majka S; Carr M; Harral J; Crona D; Kuriyama T; West J
    Am J Physiol Lung Cell Mol Physiol; 2007 Jun; 292(6):L1556-63. PubMed ID: 17369292
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Raf/ERK drives the proliferative and invasive phenotype of BMPR2-silenced pulmonary artery endothelial cells.
    Awad KS; Elinoff JM; Wang S; Gairhe S; Ferreyra GA; Cai R; Sun J; Solomon MA; Danner RL
    Am J Physiol Lung Cell Mol Physiol; 2016 Jan; 310(2):L187-201. PubMed ID: 26589479
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone morphogenetic protein receptor-2 signaling promotes pulmonary arterial endothelial cell survival: implications for loss-of-function mutations in the pathogenesis of pulmonary hypertension.
    Teichert-Kuliszewska K; Kutryk MJ; Kuliszewski MA; Karoubi G; Courtman DW; Zucco L; Granton J; Stewart DJ
    Circ Res; 2006 Feb; 98(2):209-17. PubMed ID: 16357305
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenotypically Silent Bone Morphogenetic Protein Receptor 2 Mutations Predispose Rats to Inflammation-Induced Pulmonary Arterial Hypertension by Enhancing the Risk for Neointimal Transformation.
    Tian W; Jiang X; Sung YK; Shuffle E; Wu TH; Kao PN; Tu AB; Dorfmüller P; Cao A; Wang L; Peng G; Kim Y; Zhang P; Chappell J; Pasupneti S; Dahms P; Maguire P; Chaib H; Zamanian R; Peters-Golden M; Snyder MP; Voelkel NF; Humbert M; Rabinovitch M; Nicolls MR
    Circulation; 2019 Oct; 140(17):1409-1425. PubMed ID: 31462075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BMPR2 Loss Activates AKT by Disrupting DLL4/NOTCH1 and PPARγ Signaling in Pulmonary Arterial Hypertension.
    Awad KS; Wang S; Dougherty EJ; Keshavarz A; Demirkale CY; Yu ZX; Miller L; Elinoff JM; Danner RL
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of bone morphogenetic protein receptor 2 is associated with abnormal DNA repair in pulmonary arterial hypertension.
    Li M; Vattulainen S; Aho J; Orcholski M; Rojas V; Yuan K; Helenius M; Taimen P; Myllykangas S; De Jesus Perez V; Koskenvuo JW; Alastalo TP
    Am J Respir Cell Mol Biol; 2014 Jun; 50(6):1118-28. PubMed ID: 24433082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of serum deprivation on constitutive production of granulocyte-colony stimulating factor and granulocyte macrophage-colony stimulating factor in lung cancer cells.
    Uemura Y; Kobayashi M; Nakata H; Harada R; Kubota T; Taguchi H
    Int J Cancer; 2004 May; 109(6):826-32. PubMed ID: 15027115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone morphogenetic protein (BMP) type II receptor deletion reveals BMP ligand-specific gain of signaling in pulmonary artery smooth muscle cells.
    Yu PB; Beppu H; Kawai N; Li E; Bloch KD
    J Biol Chem; 2005 Jul; 280(26):24443-50. PubMed ID: 15883158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.